

# foi



\* 5210490 \*



\* A \*

**5210490 A**

Alora 0.025mg, 0.05mg, 0.075mg, 0.1mg  
Transdermal System (Watson Laboratories)  
04/05/2002 Approval [Postmenopausal  
Osteoporosis]: Approval Letter; Approvable Letter;  
Final Labeling

**This document was provided by: FOI Services, Inc**

11 Firstfield Road  
Gaithersburg MD 20878-1704 USA  
Phone: 301-975-9400  
Fax: 301-975-0702  
Email: [infofoi@foiservices.com](mailto:infofoi@foiservices.com)

**Do you need additional U.S. Government information?**

Since 1975, FOI Services, Inc has specialized in acquiring government files using the Freedom of Information Act. We have millions of pages of unpublished documentation already on file and available for immediate delivery.

**Many of the documents you need are available for immediate downloading at:**

***[www.foiservices.com](http://www.foiservices.com)***

Unless specified otherwise, all of FOI Services' documents have been released by the U.S. Government under the provisions of the Freedom of Information Act and are therefore available to the general public. FOI Services, Inc. does not guarantee the accuracy of any of the information in these documents; the documents will be faithful copies of the information supplied to FOI Services, Inc.

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Application Number** NDA 21-310

**APPROVAL LETTER**



NDA 21-310

Watson Laboratories, Inc.  
Attention: Dorothy A. Frank, M.S., R.A.C.  
Executive Director, Proprietary Regulatory Affairs  
417 Wakara Way  
Salt Lake City, UT 84108

Dear Ms. Frank:

Please refer to your new drug application (NDA) dated January 12, 2001, received January 16, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Alora (estradiol transdermal system) 0.025 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day.

Your submission of February 5, 2002, constituted a complete response to our January 18, 2002, action letter.

This new drug application provides for 1) addition of a 0.025 mg/day strength product and 2) addition of an indication for the prevention of postmenopausal osteoporosis for all strengths.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert) and submitted draft labeling (pouch and carton labels submitted on November 15, 2001). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-310." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We are waiving the pediatric study requirement for this action on this application.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA, NDA 20-655, for this drug product, not to this NDA. In the future, do not make submissions to this NDA except for the final printed labeling requested above.

If you have any questions, call Samuel Y. Wu, Pharm.D., Regulatory Project Manager, at 301-827-6416.

Sincerely,

*(See appended electronic signature page)*

David G. Orloff, M.D.  
Director  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure

**APPEARS THIS WAY  
ON ORIGINAL**

**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**

/s/

David Orloff

4/5/02 01:11:46 PM

**APPEARS THIS WAY  
ON ORIGINAL**

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.